AACRpublished
Abstract 4444: Integrin alpha-2 (ITGA2) is a novel and well-suited antibody-drug conjugate (ADC) target
AACR published an abstract describing ITGA2 as a novel and well-suited antibody-drug conjugate target and referencing IPN60300 in the ITGA2-targeted ADC context.
2026-04-03 Foreseen Biotechnology Public article URL ready for sharing
AACR Journals published Abstract 4444 in Cancer Research, describing integrin alpha-2 (ITGA2) as a novel and well-suited antibody-drug conjugate target.
The abstract record references IPN60300 in the context of an ITGA2-targeted ADC and provides additional public context for the target biology behind the FS001 / IPN60300 program.
Source: Cancer Research / AACR Journals. DOI: https://doi.org/10.1158/1538-7445.AM2026-4444.
Collaboration & media inquiries
For additional information about the platform, pipeline or partnership opportunities, submit an inquiry through the contact page.
Contact Foreseen